NCT06631079View on ClinicalTrials.gov

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2028

Conditions
Solid Tumor
Interventions
BIOLOGICAL

NECVAX-NEO1

Bacteria-based orally administered personalised neoantigen-targeting cancer vaccine

Trial Locations (8)

Unknown

RECRUITING

Charité, Berlin

RECRUITING

NCT, Heidelberg

RECRUITING

Comprehensive Cancer Center, Munich

RECRUITING

National Cancer Center, Vilnius

RECRUITING

Institut Catala d'Oncologia, Barcelona

RECRUITING

Vall d'Hebron, Barcelona

RECRUITING

Fundacion Jimenez Diaz, Madrid

RECRUITING

CHUS Santiago de Compostela, Santiago de Compostela

Sponsors

Lead Sponsor

NEC Bio B.V

Collaborators (1)

NEC Bio Therapeutics
All Listed Sponsors
collaborator

NEC Bio Therapeutics

INDUSTRY

lead

NEC Bio B.V

INDUSTRY

NCT06631079 - Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter